Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07130643) titled 'Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer' on Aug. 12.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Xinhong Wu, PhD
Condition:
HR+/HER2- Breast Cancer
Intervention:
Drug: CDK4/6 inhibitors+Endocrine Therapy
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 20, 2024
Target Sample Size: 40
Countries of Recruitment:
China
To know more, visit https://clini...